TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00565279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASF1057
Description: Twice daily, topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASF1057
Description: Twice daily, topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASF1057
Description: Twice daily, topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASF1057
Description: Twice daily, Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASF1057
Description: Twice daily, Topical
Study: NCT03279276

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.~By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Description: The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.~By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector.
Study: NCT04115358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid: Gengigel teething
Description: Applying of 0,54% hyaluronic acid for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol Buckley formula: Formacresol
Description: Applying of 1/5 diluted formocresol for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ferric sulfate: ViscoStat
Description: Applying of 20% ferric sulfate for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
Study: NCT00657709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)
Description: One dose of rMenB concomitantly with the routinely administered infant vaccines
Study: NCT01205165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefor dipivoxil
Description: All enrolled subjects were enrolled to adefovir dipivoxil arm.
Study: NCT01049724

Intervention type: OTHER
Intervention: Tear collection
Description: Tear collection

Intervention type: OTHER
Intervention: Tear collection
Description: Tear collection
Study: NCT01149798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane and Cisplatin combination
Description: Abraxane will be given at 125 mg/m2, venous infusion within 30 minutes, administered on days 1, 8 and 15.~Cisplatin at 75mg/m2, venous infusion for 120 minutes, will be administered on day 1.
Study: NCT02121340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Study: NCT04065919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: 20mL EXPAREL+40mL bupivacaine 0.25% infiltrated into 5th intercostal space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine with epinephrine
Description: 0.25% Bupivacaine with epinephrine at 1cc/kg total dose infiltrated into 5th intercostal space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine with epinephrine
Description: 0.25% Bupivacaine with epinephrine at 1cc/kg total dose infiltrated into 5th intercostal space
Study: NCT00003694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omacetaxine mepesuccinate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02051972

Intervention type: DEVICE
Intervention: Implanted with a Nanostim leadless pacemaker system
Study: NCT03027466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation induction
Description: Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition). Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-affirmation induction
Description: Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition). Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.
Study: NCT00657709

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix Hexa
Description: Routine vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix Hexa
Description: Routine vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate
Description: One dose of the routinely administered infant vaccines + MenC vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Description: Routine vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Description: Routine vaccination
Study: NCT03027466

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-affirmation induction
Description: Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition). Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-affirmation induction
Description: Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition). Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.
Study: NCT03022617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Study: NCT02172937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decidual Stromal Cells thawed in plasma
Study: NCT04292756

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: OKT
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: IOP
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: IOP
Description: Ophthalmic examination
Study: NCT00502749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Daily group or personal exercise programs designed to promote flexibility, endurance, and strength.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires taking 15 minutes to complete.
Study: NCT00890409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling cap (YJW608-04B)
Description: A semiconductor water circulation cooling device (YJW608-04B, Henyang Radio Manufactory, Hunan, China) was used to conduct head cooling. The hypothermia group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
Study: NCT02206100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER977
Description: reversal of edoxaban-induced anticoagulation
Study: NCT03761251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pet Fish
Description: Participants will be provided a fish tank with supplies to care for the fish and access to a fish (Betta splendens) from a local pet store. All participants will receive specific instructions for coupling the fish care and diabetes care:~1. feed fish one pellet in the morning after waking; check and record BG reading at that time~2. feed fish one pellet in the evening before dinner; check and record BG reading at that time~3. feed fish one pellet at night before bedtime; check and record BG reading at that time~4. every week clean the tank alternating with test the water quality in partnership with caregiver; review blood glucose readings with caregiver with each weekly fish care activity and problem solve any issues related to the blood glucose pattern.~Each child will also receive two books intended to supplement and enrich their pet fish experience.
Study: NCT01624727

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 acid ethyl esters
Description: Lovaza 3.6 g daily
Study: NCT01826175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
Study: NCT01706250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (2.5% BPO) Foam Cleanser
Description: Available over the counter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (2.5% BPO) Foam Treatment
Description: Available over the counter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
Description: Available over the counter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PROACTIV (2.5% BPO) Renewing Cleanser
Description: Available over the counter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PROACTIV (2.5% BPO) Repairing Lotion
Description: Available over the counter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PROACTIV (2.5% BPO) Revitalizing Toner
Description: Available over the counter.
Study: NCT02172937

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Decidual Stromal Cells thawed in human albumin
Study: NCT02085824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran
Study: NCT05540951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIC
Description: VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Plus Chemotherapy
Description: Bevacizumab Plus Doublet or Triplet Chemotherapy
Study: NCT02206100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER977
Description: reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER977
Description: reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER977
Description: reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Reversal of edoxaban-induced anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Study: NCT05356871

Intervention type: OTHER
Intervention: VO2max validity and reliability assesment
Description: Reliability assessment of VO2max determination with three repeated measures for two methods.
Study: NCT02812524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intratumoral Ipilimumab
Description: Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor.
Study: NCT01366924

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Amino Acids
Description: 10 Gram Essential Amino Acid solutions with different leucine contents consumed during two identical endurance exercise trials
Study: NCT02130375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the IncontiLaseTM procedure
Description: Utilizing laser (IncontiLaseTM) to treat the anterior vaginal wall area to intensify periurethral tissue and achieve urinary continence
Study: NCT04182581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA/CD19 Dual-Target CAR-T
Description: BCMA/CD19 Dual-Target CAR-T target both BCMA and CD19. The subjects will receive CAR-T as one dose. The dosage ranges from 5×10\^4 to 3×10\^5 CAR+T/Kg.
Study: NCT02315235

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline is injected in one leg of patient.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: stem-cell
Description: Granulocyte colony-stimulating factor (G-CSF) is injected into subcutaneous for three days prior to the blood collection (D-3 to D-1). Peripheral mononuclear stem-cell is collected by Cobe spectra apheresis system in D-day.~The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient.
Study: NCT04224766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular Nerve Block with 5ml bupivicaine 0.5%
Description: The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of bupivicaine 0.5%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: costoclavicular Block 10ml bupivicaine 0.5%
Description: transverse ultrasound imaging of the medial infraclavicular fossa to identify the cords of the brachial plexus at the costoclavicular space (CCS) then inject 10ml bupivicaine 0.5%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Brachial Plexus Block 15ml bupivicaine 0.5%
Description: The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of bupivacaine 0.5%.
Study: NCT04520945

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Chondrogen
Description: Mesenchymal stem cell-derived from umbilical cord Wharton Jelly and hyaluronic acid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consist of saline and hyaluronic acid
Study: NCT01366924

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Amino Acids
Description: 10 Gram Essential Amino Acid solutions with different leucine contents consumed during two identical endurance exercise trials

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Essential Amino Acids
Description: 10 Gram Essential Amino Acid solutions with different leucine contents consumed during two identical endurance exercise trials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance exercise
Description: 60 minute endurance exercise session
Study: NCT00212446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Intervention (EI)
Description: Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
Study: NCT01038076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MedCHEC Tablet Computer & Adherence Care
Description: Patients answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates patient and provider reports. Patients may be referred to an Adherence Care Manager on the basis of the reports.
Study: NCT02452606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stalevo®
Description: * Sleep disorders in Parkinson's disease~* Analysis by Parkinson's Disease Sleep Scale(PDSS) scores.~* If the PDSS score is improving at least 15 percent than the baseline score, It can be determined to be effective.
Study: NCT04515147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV 6 μg
Description: Participants will receive an intramuscular injection by needle in the deltoid area.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV 6 μg
Description: Participants will receive an intramuscular injection by needle in the deltoid area.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV 12 μg
Description: Participants will receive an intramuscular injection by needle in the deltoid area.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV 12 μg
Description: Participants will receive an intramuscular injection by needle in the deltoid area.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Participants will receive an intramuscular injection by needle in the deltoid area.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Participants will receive an intramuscular injection by needle in the deltoid area.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine
Description: Participants will receive an intramuscular injection by needle in the deltoid area.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine
Description: Participants will receive an intramuscular injection by needle in the deltoid area.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV 12μg
Description: Participants will receive an intramuscular injection by needle in the deltoid area.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV 12μg
Description: Participants will receive an intramuscular injection by needle in the deltoid area.
Study: NCT02555579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Protein Counting and Free Fruits and Vegetables
Description: Subjects will be educated on new simplified diet approach and phenylalanine levels will be monitored for 1 year, and will be compared to 12 months prior to study enrollment